Back to Results
First PageMeta Content
Biology / Ciclosporin / Novartis / Peptides / Vernal keratoconjunctivitis / Keratoconjunctivitis / Pharmaceutical drug / Conjunctivitis / Health / Medicine / Immunosuppressants


News Release Santen Receives Manufacturing and Marketing Approval for its Vernal Keratoconjunctivitis Treatment, PAPILOCK Mini Ophthalmic Solution 0.1% October 12, 2005, Osaka, Japan -- Santen Pharmaceutical Co., Ltd. (
Add to Reading List

Document Date: 2013-08-06 15:12:37

Open Document

File Size: 14,10 KB

Share Result on Facebook

City

Osaka / /

Company

Novartis AG / Novartis Pharma AG / News Release Santen Receives Manufacturing / Santen Pharmaceutical Co. Ltd. / /

Country

Switzerland / Japan / /

Event

FDA Phase / /

IndustryTerm

pharmaceutical division / ophthalmic solution / manufacturing / /

MedicalCondition

allergies / persistent ocular disease / Vernal Keratoconjunctivitis / /

MedicalTreatment

surgery / /

Organization

Ministry of Health / /

Person

Takakazu Morita / /

Position

President / /

Product

Neoral / PAPILOCK Mini Ophthalmic Solution / PAPILOCK / ophthalmic / /

SocialTag